Retatrutide Just Posted 28.7% Weight Loss. Here’s What That Actually Means
Everyone loves quoting big percentage drops, but “28.7% weight loss” only hits when you translate it: that’s 71 pounds gone in 68 weeks for the average person who enrolled in TRIUMPH-4. The same once-weekly shot also took knee pain scores down by three quarters. You almost never see weight control and osteoarthritis relief move together like that, which is why this readout matters far beyond the obesity echo chamber.
If you have obesity plus joint damage, you live in a loop. Less movement worsens cartilage wear. More pain encourages even less movement. Existing GLP-1 drugs can shrink the number on the scale, but they barely touch mechanical pain. Retatrutide is the first agent that shows it might manage both sides at the same time. at least in people who stuck with the top doses.
How a triple agonist nudges your metabolism on three fronts
Retatrutide hits three peptide receptors at once: GLP-1, GIP, and glucagon. GLP-1 slows gastric emptying and reins in appetite. GIP pushes the pancreas to release insulin when you eat. Glucagon usually raises glucose, but when you stimulate it alongside GLP-1 you get a thermogenic effect, so your body burns more calories at rest. Lilly titrated doses over several weeks (2 mg → 4 mg → 6 mg → 9 mg or 12 mg) to avoid overwhelming the gut. By the time participants stabilized, they were seeing fasted insulin down, resting energy expenditure up, and non-HDL cholesterol and hsCRP trending lower according to Lilly’s topline deck and the Clinical Trials Arena summary.
Unlike dual agonists such as tirzepatide, the glucagon component keeps the sympathetic nervous system a little more active. That can feel uncomfortable early on. think warmth, mild tingling, or dysesthesia. but it is also why the drug shaved 14 mmHg off systolic blood pressure at the high dose. More brown fat activation means better vascular compliance. That matters if you are carrying 35+ BMI points and struggling with joint perfusion.
Inside TRIUMPH-4: 445 adults, 68 weeks, relentless titration
TRIUMPH-4 randomized 445 adults with obesity or overweight plus diagnosed knee osteoarthritis. Average baseline: 112.7 kg, BMI 40.4, WOMAC pain 6.0 out of 10. Eighty four percent had BMI ≥35. Participants cycled through titration every four weeks until they landed on 9 mg or 12 mg, then held that for the remainder of the 68-week period.
Results using the efficacy estimand:
- 9 mg arm: –26.4% body weight (64 pounds) and –4.5 WOMAC pain points.
- 12 mg arm: –28.7% body weight (71 pounds) and –4.4 WOMAC pain points.
- Placebo: –2.1% weight and –2.4 pain points.
Half the people on 12 mg hit at least 25% weight loss, 39% crossed 30%, and nearly a quarter crossed 35%. Pain responders were just as dramatic: 73% of the 9 mg group and 68% of the 12 mg group saw ≥70% pain reduction, compared with 26% on placebo. In a post-hoc slice, 14.1% of 9 mg patients and 12% of 12 mg patients ended the trial with zero measurable knee pain. Only 4.2% of placebo patients could say the same.
Secondary biomarkers moved in a cardiometabolic-friendly direction. Non-HDL cholesterol dropped, triglycerides fell, hsCRP fell, and systolic blood pressure declined 14 mmHg at the top dose. These shifts are consistent with removing visceral fat and tamping down systemic inflammation, which should compound the orthopedic benefits.
The side effects nobody mentions in press releases
This is not a gentle ride. Nausea hit 38% at 9 mg and 43% at 12 mg. Diarrhea hovered around one third. Constipation around one quarter. Vomiting around one fifth. Those numbers look similar to tirzepatide but are all concentrated into higher-dose cohorts, so people who do not ramp slowly are more likely to bail.
The unique signal here is dysesthesia. odd sensations, pins and needles, or hot-cold swings. in 8.8% of the 9 mg arm and 20.9% of the 12 mg arm. It rarely forced a drop-out, yet it is a clue that aggressive glucagon signaling is doing more than curbing appetite. You are pushing the nervous system. Anyone with neuropathy or Raynaud’s should keep that in mind.
Discontinuation rates due to adverse events were 12.2% (9 mg), 18.2% (12 mg), and 4% (placebo). That is manageable but not trivial. Remember: the efficacy numbers above assume perfect adherence. In the treatment-regimen analysis. which counts people who stopped dosing. weight loss landed at –20.0% and –23.7% for 9 mg and 12 mg respectively. Still great. Just less dramatic than the headlines.
Why osteoarthritis patients should care
Dropping weight is the obvious benefit. The wild card is pain relief. WOMAC pain scores sit on a 0-10 scale. Cutting 4.5 points translates to moving from “constant ache that messes with stairs” down to “occasional discomfort after a long walk.” That lines up with the functional data: WOMAC physical function scores fell ~4.2 points, signaling better gait, easier chair stands, and fewer night awakenings.
If that holds up in real-world use, retatrutide could delay knee replacements for people in their 40s and 50s long enough to avoid a revision later. Orthopedic surgeons usually ask patients to lose weight before surgery anyway. A drug that simultaneously trims mass and soothes inflammation gives them a cleaner path to the OR or lets them postpone the procedure entirely.
There is another bonus: knee osteoarthritis flares when systemic inflammation is elevated. Retatrutide’s hsCRP drop hints that the triple agonist combo calms cytokine activity, which could protect cartilage indirectly. That needs cartilage imaging proof, but it is a plausible mechanism.
What to watch next
Seven more retatrutide Phase 3 trials will read out in 2026, including TRIUMPH-1, which runs 80 weeks and adds a 4 mg maintenance arm. Lilly is open about the goal: show 30%+ weight loss in a general obesity population without joint disease, then carve out high-risk subgroups (sleep apnea, fatty liver, osteoarthritis) where insurers are likelier to pay.
The commercial wrinkle is supply. Triple-agonist manufacturing is trickier than GLP-1-only peptides, and Lilly is already stretching its capacity for tirzepatide. Expect early access programs to prioritize the heaviest patients with comorbid pain who cannot tolerate surgery. If you are already on Zepbound and tolerating it well, do not expect an automatic upgrade. The titration burden alone will scare off casual users.
For now, the signal is clear: stacking GIP, GLP-1, and glucagon may finally let obesity care venture beyond the scale. A drug that can peel off 70 pounds, lower blood pressure, drop hsCRP, and let you climb stairs without grimacing is more than vanity medicine.
Takeaways
- Retatrutide delivered –28.7% weight loss and a 75.8% drop in knee pain after 68 weeks in TRIUMPH-4, beating every approved incretin on both metrics.
- The triple agonist design attacks appetite, insulin control, and resting energy expenditure simultaneously, which explains the blood pressure and inflammation wins.
- Side effects remain classic incretin complaints plus a notable dysesthesia signal, and nearly one in five people on 12 mg stopped because of adverse events.
- Pain relief is not a sideshow. up to 14% ended the trial with zero knee pain, suggesting a path to delaying joint replacement for high-BMI patients.
- Supply and tolerability will dictate real-world impact until Lilly scales production and releases data from the remaining Phase 3 trials.
This is educational content, not medical advice. Talk to your doctor before starting any protocol.